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Objective: Current histological scoring methods to evaluate efﬁcacy of potential therapeutics for slowing
or preventing joint degeneration are time-consuming and semi-quantitative in nature. Hence, there is a
need to develop and standardize quantitative outcome measures to deﬁne sensitive metrics for studying
potential therapeutics. The objectives of this study were to use equilibrium partitioning of an ionic
contrast agent via Equilibrium Partitioning of an Ionic Contrast-Microcomputed tomography (EPIC-mCT)
to quantitatively characterize morphological and compositional changes in the tibial articular cartilage in
two distinct models of joint degeneration and deﬁne localized regions of interest to detect degenerative
cartilage changes.
Materials and Methods: The monosodium iodoacetate (MIA) and medial meniscal transection (MMT) rat
models were used in this study. Three weeks post-surgery, tibiae were analyzed using EPIC-mCT and
histology. EPIC-mCT allowed measurement of 3D morphological changes in cartilage thickness, volume
and composition.
Results: Extensive cartilage degeneration was observed throughout the joint in the MIA model after
3 weeks. In contrast, the MMT model showed more localized degeneration with regional thickening of
the medial tibial plateau and a decrease in attenuation consistent with proteoglycan (PG) depletion. Focal
lesions were also observed and 3D volume calculated as an additional outcome metric.
Conclusions: EPIC-mCT was used to quantitatively assess joint degeneration in two distinct preclinical
models. The MMT model showed similar features to human Osteoarthritis (OA), including localized
lesion formation and PG loss, while the MIA model displayed extensive cartilage degeneration
throughout the joint. EPIC-mCT imaging provides a rapid and quantitative screening tool for preclinical
evaluation of OA therapeutics.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) affects 26.9 million people in the US1.
Current treatment methods are targeted towards pain relief for OA
often in the form of non-steroidal anti-inﬂammatory drugs
(NSAIDs)2. However, there are currently no clinically approvedR.E. Guldberg, Parker H. Petit
st Drive, Georgia Institute of
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.
s Research Society International. Ptherapeutics that can halt the progression of OA by controlling
cartilage erosion and chondrocyte loss3.
Developing disease modifying osteoarthritis drugs (DMOADs)
remains an unmet need for OA patients. Animal models used for
assessing therapeutic effects of these drugs, such as matrix met-
alloproteinase inhibitors (MMPi), have traditionally used histology
as an endpoint readout4e7. Histology remains the universal tool to
assess the health of articular cartilage in animal models, but mul-
tiple histopathology scoring methods exist8. No system is consis-
tently accepted as the standard8e10. The screening rate of drugs is
currently limited by the sensitivity of the scoring method (semi-
quantitative pathology scoring), requiring a large number of sam-
ples and extensive time commitment. As additional disadvantages,
histology is destructive, time consuming and typically represents
only a 2D analysis. Therefore, there is a need to developublished by Elsevier Ltd. All rights reserved.
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eration to provide platforms to better understand joint diseases
and to evaluate the efﬁcacy of potential therapeutics.
The need to develop new imaging technologies is not limited to
just studying potential therapeutics. Anatomical and chemical
composition of structures can be characterized using these new
imaging modalities allowing for long-term in-vivo monitoring of
development and progression of joint diseases. These techniques
have been critical to progress in ﬁelds such as cancer research and
cardiology, but have thus far been limited in orthopedics mainly
due to presence of multiple different tissue structures, resolution
and acquisition time of images11.
Microcomputed tomography (mCT) has traditionally provided
3D, quantitative analysis of hard tissues. This imaging methodology
has recently been modiﬁed to facilitate application to soft tissues,
such as cartilage, using contrast agents. Equilibrium Partitioning of
an Ionic Contrast agent via mCT (EPIC-mCT), allows for non-
destructive evaluation of cartilage morphology and composi-
tion12. Cartilage degeneration results in a depletion of negatively
charged proteoglycans (PGs). This depletion allows for more of the
negatively charged contrast agent to diffuse into the cartilage ma-
trix compared to healthy tissue. The X-ray attenuation of equili-
brated tissue has previously been shown to have an inverse
relationship with sulfated glycosaminoglycans (sGAG) content
(validated by Safranin-O optical density and the 1,9-
dimethylmethylene blue colorimetric assay) resulting in higher
attenuation values for degenerated tissue12,13. Morphological
measurements with EPIC-mCT have been validated compared to
measurements of cartilage thickness (histomorphometry and
needle probe testing) and demonstrated a strong linear relation-
ship13. This presents a quantitative metric for analyzing cartilage
composition and detecting changes in cartilage quality in addition
to 3D morphology. Previous studies have used different variations
of mCT, such as EPIC-mCT and in vivo mCT arthrography to image
cartilage in multiple joint degeneration models13e19.
Several surgically and chemically induced models of OA have
been developed in different species as platforms to evaluate dis-
ease pathology as well as to screen therapeutics20,21. In this study,
two joint degeneration rat models commonly used to screen OA
therapies were characterizeddchemical induction of joint degen-
eration using monosodium iodoacetate (MIA) and surgical induc-
tion of joint degeneration via medial meniscal transection
(MMT)20,22. Each method presents advantages for use in small
animal models of joint degeneration. The MIA model is quick, easy,
reproducible, and animals exhibit signs of OA related pain23. The
MMT model, is characterized by progressive cartilage degeneration
involving chondrocyte and PG loss, osteophyte and lesion forma-
tion, collagen degradation and cartilage ﬁbrillation5,8,24,25. A major
difference in the two models is that the MIA model leads to global
degenerative changes whereas the MMT model leads to more
localized damage. The MIA model is also typically more aggressive
and associated with increased joint pain. While a high dose MIA
modeldwhere PGs are nearly completely depleteddhas previ-
ously been characterized using EPIC-mCT15, EPIC-mCT has not been
used to characterize a less aggressive low dose MIA model or the
MMT model.
EPIC-mCT allows for high-resolution 3D quantiﬁcation of
cartilage morphology and composition. It is a relatively high
throughput technique, provides 3D volumetric data, and enables
increased sensitivity and 3D visualization. The objectives of this
study were to use EPIC-mCT to quantitatively characterize
morphological and compositional changes in the tibial articular
cartilage in two distinct models of joint degeneration and deﬁne
localized regions of interest to detect degenerative cartilage
changes.Methods
Induction of joint degeneration
Georgia Institute of Technology Institutional Animal Care and
Use Committee approved all experimental animal procedures
(IACUC protocol #A09007). Two groups of rats were used in this
study e 8-week old Wistar rats injected with MIA and weight
matched Lewis rats (300e325 g) that underwent MMT
surgery5,15,26.
Eight 8-week old male Wistar rats (Charles River, Wilmington,
MA) were acclimated for 1 week. After anesthetizing with iso-
ﬂurane, 0.3 mg MIA (SigmaeAldrich, St. Louis, MO) in 50 ml saline
was injected into the joint space through the infrapatellar ligament
of the left knee. Right knees were injected with 50 ml saline as a
contralateral control.
Seven weight matched adult male Lewis rats (Charles River,
Wilmington, MA; 300e325 g) were acclimated for 1 week. The
animals were anesthetized with isoﬂurane, and a small incision
through the skinwas made on the medial aspect of the left femoro-
tibial joint. The medial collateral ligament (MCL) was exposed by
blunt dissection and transected to visualize the joint space and
medial meniscus. The meniscus was transected completely at its
narrowest point. The skin was closed with 4.0 silk sutures and then
stapled using wound clips. All surgical sites were observed daily for
signs of abnormal healing.
Assessment of cartilage
Rats were euthanized via CO2 inhalation at 3 weeks after MIA
injection or MMT surgery. Tibiae were harvested, dissected free of
surrounding tissues, and ﬁxed in 10% neutral buffered formalin
(NBF, EMD Chemicals, Gibbstown, NJ) for 3e4 days and then
transferred to 70% ethanol12.
For EPIC-mCT, the proximal end of each tibia was immersed in
2 ml of 30% Hexabrix 320 contrast agent (Covidien, Hazelwood,
MO) and 70% ion-free phosphate buffer saline (PBS) at 37 C for
30min, an incubation period known to result in equilibration of the
agent12,13. There was no difference in the average X-ray attenuation
levels, thickness, volume or surface area determined for fresh and
formalin-ﬁxed cartilage at that time point (Fig. S1). Proximal tibiae
were scanned using a mCT 40 (Scanco Medical, Brüttisellen,
Switzerland) at 45 kVp, 177 mA, 200 ms integration time, and a
voxel size of 16 mm13.
Following scanning, tibiae were decalciﬁed in Cal-Ex II (Fisher
Scientiﬁc, Waltham, MA) for 14 days. Samples were routinely
parafﬁn embedded. For comparison with EPIC-mCT images, sagittal
sections were cut at 5 mm thickness. Sections were stained for
sGAGs with 0.5% Safranin-O and 0.2% Fast Green counterstain or
hematoxylin & eosin. For each sample, three sagittal sections were
used for thickness histomorphometry analysis and digital images of
each section were captured. The cartilage thickness of each section
was deﬁned as the average value of ﬁve manual thickness mea-
surements at regular intervals perpendicular to the cartilage sur-
face and the values for the three sections were then averaged.
mCT regional analysis
Scanco evaluation software was used to assess 3D morphology
and composition. Raw scan data were automatically reconstructed
to 2D grayscale tomograms. These were rotated to sagittal sections,
and the cartilage was contoured to separate it from trabecular bone
and surrounding air12,15. The cartilage was segmented using a
bandpass ﬁlter with a minimum threshold value of 175 to eliminate
air and 225 to eliminate bone from the raw image following which
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applied for both the left and right tibiae of all animals.
The MMT surgery produces localized cartilage degeneration on
the medial plateau of the tibia. To observe localized effects of joint
degeneration, we evaluated the medial tibial plateau in the MMT
group. The regional analyses were replicated for the MIA tibiae for
comparison. Four regional analyses were performed using different
volumes of interest (VOI). For the MMT model, images were eval-
uated for: (1) Full articular cartilage in the proximal tibia including
medial and lateral aspects (2) Medial plateau only (3) Medial 1/3 of
the medial tibial plateau (4) Focal lesions on the medial plateau
only (Fig. 1). For the MIA model, only analyses (1) and (2) were
performed for overall tibial articular cartilage and tibial medial
articular cartilage respectively. Two outcome measures were
deﬁned for evaluation of focal defects: erosion (defect extended to
less than 50% of cartilage thickness) and lesion (defect extended to
more than 50% of cartilage thickness)27. To deﬁne VOIs of focal le-
sions, manual contouring was performed in the isolated lesion area
(typicallyw8 slices). Within this VOI, segmented cartilage volume
was subtracted from the total volume evaluated to compute lesion
volume.Statistical analysis
All data were expressed as mean  standard deviation of the
mean. The means of cartilage morphology variablesdcartilage
thickness, volume, and attenuationdﬁt a Gaussian distribution
(KolmogoroveSmirnov test) and were evaluated using paired
t-tests to compare experimental and control tibiae for MMT and
MIA groups separately. Each individual region (overall cartilage,
medial tibial plateau and medial 1/3 of medial tibial plateau) was
evaluated independently with separate paired t-tests for each ofFig. 1. Representative image illustrating EPIC-mCT image analysis (tibial cartilage overlaid
bottom) displays larger thicknesses in red and smaller thicknesses in blue/green. B: Represen
shows zoomed in view). Lesion locations were identiﬁed by manually examining sagittal gthe cartilage morphology variables listed above. All analysis was
done using GraphPad Prism (GraphPad Software Inc. 5.01, La Jolla,
CA). Statistical signiﬁcance was set at a 95% conﬁdence interval
(P < 0.05). A P-value correction factor was not used in this analysis
as direct comparisons between the three regions were not per-
formed. For reference, the results with the incorporation of a
P-value correction factor are presented in the supplementary ma-
terial (Figs. S2 and S3).Results
MIA articular cartilage analysis
Representative images of tibial articular cartilage sections
stained with Safranin-O in comparison with EPIC-mCT images are
shown [Fig. 2(A,C,D and F)]. At 3 weeks post injection, the MIA
cartilage displayed extensive PG loss (2D), which was not observed
in the saline injected contralateral control (2A). Images of sagittal
sections from the medial tibial plateau of the tibia generated by
EPIC-mCT for MIA samples are also shown [Fig.. 2(B and E)].Using
the EPIC-mCT technique, the overall tibial cartilage was quantita-
tively evaluated for thickness, volume, and attenuation. At 3 weeks
post injection, cartilage thickness in MIA tibiae decreased by 30%
(P < 0.0001) compared to saline contralateral controls [Fig. 3(A)].
Cartilage attenuation in MIA tibiae increased by 18% (P ¼ 0.043)
compared to saline contralateral controls [Fig. 3(C)].
Following overall cartilage analysis, the medial tibial articular
cartilage was evaluated separately. Average cartilage thickness and
volume were 31% (P < 0.0001) and 18% (P ¼ 0.0033) lower,
respectively, compared to saline contralateral controls [Fig.. 3(D
and E)]. Average attenuation was 22% (P ¼ 0.0005) higher thanon bone) and volume of interest (VOI) designations. Pseudocolor coding (indicated at
tative grayscale EPIC-mCT images of cartilage showing erosions (B) and lesion (C) (Inset
rayscale images slice by slice.
Fig. 2. Representative images of tibial articular cartilage from saline contralateral control and MIA injected knees at 3 weeks post injection. AeC: Representative saline contralateral
control section, Safranin-O stained, 4 (A), corresponding EPIC-mCT thickness map from the same sample (B) and 10 Safranin-O section (C). DeF: Representative MIA injected
sections, Safranin-O stained, 4 (D), corresponding EPIC-mCT thickness map from the same sample (E) and 10 Safranin-O section (F).
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volume was not observed when assessing the overall tibial plateau.
MMT tibial articular cartilage analysis
Representative images of tibial articular cartilage sections
stained with Safranin-O in comparison with EPIC-mCT images are
shown [Fig. 4(A,C,D and F)]. TheMMTcartilage displayed erosion on
the histology image [Fig. 4(D and F)], which was not observed on
the contralateral control. The EPIC-mCT image of the MMT tibia also
displayed both an erosion and a lesion on the sagittal section of the
medial tibial plateau [Fig. 4(E)]. Cartilage histomorphometry mea-
surements similarly showed a signiﬁcant increase in the thickness
of the medial tibial plateau in the MMT tibiae compared to the
contralateral controls (Fig. S4).
Using the EPIC-mCT technique, the overall tibial cartilage was
quantitatively evaluated for thickness, volume, and attenuation for
the medial and lateral plateaus combined. The MMT joints did not
show any difference in thickness [Fig. 5(A)]. Average volume was
signiﬁcantly higher in the MMT tibiae (26.6%, P < 0.0001)
compared to the contralateral controls [Fig. 5(B)]. No signiﬁcantdifference in cartilage attenuation was observed when analyzing
the overall tibial cartilage [Fig. 5(C)].
The MMT medial tibial cartilage had signiﬁcantly higher thick-
ness and volume by 31% (P ¼ 0.0028) and 70% (P ¼ 0.0259)
compared to contralateral controls [Fig. 5(D and E)]. In the analyses
of cartilage in the full tibial plateau, cartilage attenuation was 25%
(P ¼ 0.0003) higher in the MMT medial tibiae than contralateral
controls [Fig. 5(E)]. Though no change in average attenuation was
observed for cartilage in the full tibial plateau, isolating the medial
plateau resulted in detection of a signiﬁcant difference in articular
cartilage attenuation for MMT tibiae compared to controls.MMT medial 1/3 of medial articular cartilage analysis
Following analysis of the medial tibial plateau, further localized
analysis was performed for the medial 1/3 of the medial tibial
plateau. Evaluating this region, similar results were observed as
with the whole medial plateau. Average cartilage thickness and
volume in the MMT tibiae were 50% (P < 0.0001) and 90%
(P < 0.0001) higher, respectively, compared to contralateral
Fig. 3. Tibial articular cartilage properties quantiﬁed for MIA and saline contralateral control knees (paired comparisons). AeC: Overall tibial articular cartilage variables e Cartilage
thickness (A); cartilage volume (B); cartilage attenuation (C). DeF: Medial tibial articular cartilage variables e Cartilage attenuation (D); cartilage thickness (E); cartilage volume (F).
At 3 weeks post injection, overall and medial tibial cartilage thickness fromMIA-injected joints was signiﬁcantly lower than saline contralateral control cartilage. Overall and medial
tibial cartilage attenuation from MIA-injected joints was signiﬁcantly higher than saline contralateral controls. Medial tibial cartilage volume from MIA-injected joints was
signiﬁcantly lower than saline contralateral controls. * ¼ P < .05, n ¼ 8.
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compared to controls [Fig. 6(A,C)].
The grayscale 2D images from the medial plateau of the MMT
animals were viewed slice by slice to locate, visualize, and quantify
focal defects. Pseudo-color attenuation maps were generated based
on these images. Sagittal sections from the attenuation maps
showed higher attenuation on the MMT tibiae near the lesion sites
(Fig. 7). In addition to differences in attenuation, surface defects on
the cartilage were also observed. Two MMT samples had three le-
sions and six MMT samples had one lesion each on themedial tibial
articular cartilage. Six MMT samples had one erosion and one MMT
sample had two erosions on themedial tibial articular cartilage. The
average number of lesions was 1.57  0.37 and average number of
erosions was 1.14  0.14 for the MMT tibiae, and no defects were
observed on the controls. The average lesion volume was
0.0393  0.003 mm3 for MMT tibiae, and no lesions were found on
any of the contralateral controls (Fig. 7). The average focal lesion
volume was only 7.2% of the average medial 1/3 medial cartilage
volume and 2.1% of the average medial plateau cartilage volume.
The average focal lesion volume accounted for only 0.13% of the full
cartilage volume when medial and lateral plateaus were combined.
Because lesion volumes represented such a small region in pro-
portion to the full cartilage volume, localized assessment clearly
enhanced detection of morphometric differences between MMT
and controls.
Discussion
The study of animal models of joint degeneration is essential for
evaluating potential therapeutics and understanding the patho-
genesis of cartilage loss. Studying the progression of OA in humans
is challenging because of poor evaluative tools and limited access to
diseased tissue during early development and through disease
progression. Suitable animal models for research are consistent,
reproducible, have an appropriate time frame of progression for
high-throughput screening and recapitulate human pathology25.
Cartilage degeneration has been previously demonstrated in thetwo most widely used methods of joint degeneration in small
animalsdthe MMT model5,20,26,28,29 and the MIA model29e32.
Histopathology was the primary analytical method for these pre-
vious studies. EPIC-mCT allows for efﬁcient, non-destructive 3D
imaging and localized analysis, providing quantitative methods to
assess cartilage thickness, attenuation and volume among other
variables. For this study, the MIA and MMT models were quanti-
tatively characterized via EPIC-mCT to measure localized variables
of attenuation, thickness and volume.
The results from the current low dose MIA study indicated an
overall thinning of the cartilage layer. These are consistent with a
previous dose response study for MIA, which showed that 0.3 mg
was the lowest dose that caused articular cartilage damage
covering the entire articular surface31. In another study, Safranin-O
staining indicated hypertrophied and disorganized chondrocytes as
well as degeneration of the cartilage surface at 3 weeks at the
0.3 mg dose andmore extensive damage at a 3 mg dose33. It is to be
noted that these previous studies did not assess global and regional
degeneration of the cartilage nor did they use quantitative tech-
niques. In the current study, attenuationwas signiﬁcantly increased
in the MIA joints, which was indicative of decreased PG content.
Similarly, the Safranin-O staining showed severely depleted sGAGs.
In regional analyses and the overall tibial plateau, the low-doseMIA
model showed reduced cartilage thickness, volume as well as
increased attenuation.
The MIA model remains the current standard to assess pain
therapeutics, is easy to use and is reproducible. Hence, some
studies have tested DMOADs and NSAIDs in this model due to its
widespread prevalence23,34e37. Our results showed uniform thin-
ning and PG loss even in this low dose MIA model. This is not a
typical presentation of human OA and does not correspond with
many of the OARSI recommended OA histopathology grading fea-
tures. The MIA model represents biochemically induced OA and
disease progression is expedited in the low dose model. This can be
an issue regarding the suitability of this model to test disease
modifying therapeutics for knee OA. Additionally, transcriptional
proﬁling of gene expression has shown little overlap with this
Fig. 4. Representative images of tibial articular cartilage in control and MMT knees at 3 weeks post surgery. AeC: Representative Safranin-O stained control section, 4 (A),
corresponding EPIC-mCT thickness map from the same sample (B) and 10 Safranin-O section (C). DeF: Representative Safranin-O stained MMT section, 4 (D), corresponding EPIC-
mCT thickness map from the same sample (E) and 10 Safranin-O section (F). Green arrow in D & E indicates ﬁssure site and red arrow in D & E indicates lesion site.
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causes rapid cartilage and subchondral bone damage (at<3weeks).
This extensive damage suggests that the time-frame of disease
progression is much faster in theMIAmodel than OA progression in
humans31,37,38. Thus, the MIA model shows different genetic,
compositional and morphological changes than normally observed
in human OA. Despite this, the MIA model does have an advantage
in detecting joint pain-related behaviors due to the rapid damage
caused to the articular cartilage25. It remains the more popular
model for testing therapeutics targeted towards OA symptoms but
has limited utility for testing DMOADs and as an entry point to the
chronic OA cycle.
In the MMT model, overall and regional changes in cartilage
parameters were detected. While changes were detectable at the
overall level, most were in the medial 1/3 region. This observation
that cartilage damage was most extensive in the outer 1/3 was
similar to previous reports in the rat MMT model and attributed
to the fact that this is the load bearing region that is destabi-
lized5,26,39. Though the medial 1/3 of the medial tibial plateau
displayed cartilage thickening in the MMT model, focal lesions
were also observed. A previous study supported the identiﬁcationof localized lesions in the MMT model through immunostaining
for type II collagen neoepitope antigen (TIINE) antibody29. These
lesions had not been previously quantiﬁed. Results from the
present study showed that the lesion volume accounted for a
small percentage (2.1%) of the medial plateau cartilage volume.
The lesions compared to the full tibial articular cartilage layer
occupied an even smaller fraction of the total volume, making
cartilage changes challenging to detect when performing an
overall cartilage analysis.
The increase in thickness for the medial plateau contradicts
studies that have shown cartilage thickness to be reduced in MMT
rats at 3 weeks5,26. To conﬁrm this thickness increase that was
measured via EPIC-mCT, histomorphometric measurements were
made and similarly showed a signiﬁcant increase in cartilage
thickness in the medial tibial plateau of the MMT animals
compared to contralateral controls (Fig. S4). Other studies have also
reported thickening of OA cartilage in humans, beagles and rab-
bits40e44. Another study in dogs, reported a transient episode of
chondrocyte proliferation and increased matrix production within
the lesion site and superﬁcial zone of the adjacent articular carti-
lage in response to destabilization of joints45.
Fig. 5. Tibial articular cartilage properties quantiﬁed for MMT and contralateral control knees (paired comparisons). AeC: Overall tibial articular cartilage parameters - Cartilage
thickness (A); cartilage volume (B); cartilage attenuation (C). DeF: Medial tibial articular cartilage parameters e Cartilage attenuation (D); cartilage thickness (E); cartilage volume
(F). At 3 weeks post surgery, overall and medial cartilage volume from MMT joints was signiﬁcantly higher than contralateral control cartilage. Medial tibial cartilage thickness and
attenuation from MMT joints were signiﬁcantly higher than contralateral controls. * ¼ P < .05, n ¼ 7.
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uting to the increase in thickness/volume could be cartilage-like
structures called chondrophytes. Thickening of marginal zone
cartilage and generation of chondrophytes and osteophytes has
also been reported as a result of destabilization of the joint or injury
in many animal models including the MMT model at
3 weeks20,28,45e47. A previous study hypothesized that the observed
peripheral thickening could be an adaptive or compensatory
mechanism to increase articular cartilage surface though no data
was presented on PG content40. The cartilage volume from the
MMT tibiae in the medial 1/3 region increased by 90% compared to
the control tibiae. Formation of these chondrophyte/osteophyte
structures could augmentmeasured cartilage volume and thickness
because diffusion of contrast agent into the chondrophyte would be
expected to be similar to that of articular cartilage. Even though we
observed higher volume and thickness, the average attenuation
remained higher for the MMT tibiae indicating lower cartilage
quality and depleted PG content.
OA is a multifactorial disease and there are several contributing
factors to disease progression. Focal lesions on the articular carti-
lage have been observed in humans with early stage OA, and are
considered to be among factors involved in OA progression48. The
MMT model displayed focal lesions when regional analysis wasFig. 6. Medial 1/3 medial tibial articular cartilage properties quantiﬁed for MMT and contrala
cartilage attenuation. Cartilage thickness and volume from MMT surgery tibiae were signiﬁc
surgery tibiae was signiﬁcantly higher than the respective contralateral control tibiae. * ¼performed using EPIC-mCT. While histology can identify lesions, the
2D nature of the technique means that lesion incidence and overall
volumes cannot be quantiﬁed. EPIC-mCT allowed for both slice-by-
slice visualization and volumetric quantiﬁcation of these lesions.
Our ability to further discern the sensitivity of the EPIC-mCT tech-
nique to measure more subtle PG changes was limited by the fact
that sham surgery was not performed. Contralateral control limbs
were used as negative controls as sham surgeries do not develop
lesions49, and this additionally allowed us to minimize animal
numbers. The MMT model displayed several characteristics similar
to OA characteristics in humans such as peripheral thickening, loss
of PGs, erosion of cartilage and localized lesions.
Though the objectives of this studywere not to directly compare
MIA and MMT models, some interesting overall observations exist.
The data show widespread cartilage degeneration in the low dose
MIA model and localized degradation in the MMT model. The MIA
model appears to cause greater damage in full tibial plateau carti-
lage compared to controls; whereas, this difference at the full tibial
plateau level was not detected in the MMT model at 3 weeks. It
should be noted that two different strains of rats were used in this
study. Based on previous studies, the standard rat strain for theMIA
model is Wistar and for the MMT model is Lewis8. Direct compar-
ison of absolute quantitative values are not appropriate and thus,teral control knees (paired comparisons). A: Cartilage thickness; B: cartilage volume; C:
antly higher than contralateral control cartilage. Average cartilage attenuation in MMT
P < .05, n ¼ 7.
Fig. 7. Representative EPIC-mCT images of tibial articular cartilage in control and MMT knees at 3 weeks post surgery. AeB: Representative sagittal attenuation maps of medial tibial
plateau for control (A) and MMT (B) (Inset shows zoomed in view). Red displays higher attenuation levels and green indicates lower attenuation. Red arrow indicates lesion site in
MMT. Higher levels of attenuation were seen surrounding the lesion site for MMT tibiae. C: Focal lesion volume quantiﬁcation for MMT tibiae.
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different strains to the two methods used to induce joint degen-
eration, this limitation does not alter the conclusions of the study.
Another limitation of our analysis was that all measurements were
performed in the sagittal plane as established previously in the
EPIC-mCT protocol, and this limited our ability to perform com-
parisons to the OARSI histomorphometric standards50. Future work
may involve developing a new protocol to analyze coronal sections
to compare results to current histological standards.
In summary, this study has presented a powerful technique for
quantitative assessment of localized changes associated with OA in
two important preclinical models of the disease. The data show that
the MMT model caused less extensive global damage than the MIA
model at 3 weeks. The resemblance of physical characteristics
produced in the rat MMT model to that of human OA progression
indicates that the MMT model could be a better predictive tool for
examining OA progression. The EPIC-mCT technique facilitated
rapid, quantitative assessments of cartilage morphology, cartilage
attenuation, lesions and erosions over full rat tibial articular carti-
lage as well as in delineated regions. It is a powerful technique with
the potential to signiﬁcantly improve preclinical throughput for
screening therapeutics and to provide substantially more infor-
mation than traditional histopathology reports.
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